Kopran Limited — PPTs, 12-11-2025: Investor Presentation

Kopran Limited reported HY 2025-26 revenue of Rs 253.13 Cr, with a net loss of Rs 2.47 Cr. EBITDA stood at Rs 17.09 Cr, reflecting a 6.75% margin, and EPS was -Rs 0.51. The API segment, contributing Rs 158.70 Cr, saw strong sales in Carbapenem, Intermediate, and Macrolide products, with significant local and export sales. The Formulations segment, at Rs 90.95 Cr, recorded strong regional sales in Africa and Southeast Asia.

The company's strategy focuses on R&D for niche APIs, capacity expansion including a new API & R&D facility at Panoli, and reducing reliance on China. Management is also prioritizing cost optimization, process improvements, and expanding customer reach in new geographies.